BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/19/2025 8:44:10 AM | Browse: 2 | Download: 0
Category |
Endocrinology & Metabolism |
Manuscript Type |
Retrospective Study |
Article Title |
Indirect bilirubin is inversely associated with diabetic retinopathy risk and is a potential predictive biomarker
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Xiao-Ying Lin, Yi-Xuan Zheng, Meng-Meng Liu, Qian Liang, Meng Li, Jing Sui, Wei Qiang, Hui Guo, Bing-Yin Shi and Ming-Qian He |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Natural Science Foundation of Shaanxi Province |
2024JC-YBQN-0828 |
Natural Science Foundation of Shaanxi Province |
2024JC-YBMS-765 |
Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University |
XJTU1AF-CRF-2022-036 |
National Innovation Center for Advanced Medical Devices |
NMED2023AGP-013 |
|
Corresponding Author |
Ming-Qian He, MD, Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, No.277 Yanta West Road, Xi’an 710061, Shaanxi Province, China. mingqian_he@xjtufh.edu.cn |
Key Words |
Biomarker; Diabetic retinopathy; Indirect bilirubin; Oxidative stress; Type 2 diabetes mellitus |
Core Tip |
This cross-sectional study distinguished the role of indirect bilirubin (IBIL) in diabetic retinopathy (DR) risk in patients with type 2 diabetes mellitus. IBIL levels were independently associated with a lower risk of developing DR, whereas total bilirubin and direct bilirubin were not. The optimal IBIL cutoff point for the risk of developing DR was 0.735 μmol/dL, with an area under the curve (AUC) of 0.612 in the overall population. The optimal IBIL cutoff point in male patients with elevated diastolic blood pressure was 0.655 μmol/dL, with an increased AUC of 0.662. IBIL is thus a potential predictive biomarker for DR. |
Citation |
Lin XY, Zheng YX, Liu MM, Liang Q, Li M, Sui J, Qiang W, Guo H, Shi BY, He MQ. Indirect bilirubin is inversely associated with diabetic retinopathy risk and is a potential predictive biomarker. World J Diabetes 2025; In press |
 |
Received |
|
2025-06-12 04:04 |
 |
Peer-Review Started |
|
2025-06-13 00:18 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-06-27 02:15 |
 |
Revised |
|
2025-07-10 14:23 |
 |
Second Decision |
|
2025-08-08 09:21 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-08-19 08:44 |
 |
Articles in Press |
|
2025-08-19 08:44 |
 |
Publication Fee Transferred |
|
2025-07-17 14:57 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345